Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for YCANTH (VP-102) in Common warts. The expected timing is based on the latest available company guidance and may change.
11/2020- Positive results from Ph2 clinical trial reported. 11/09/23- Completed Ph2 trial. 11/14/25- Initiate trial in the US by YE 2025. 01/07/26:- First patient dosed in Dec 2025 in global Ph3 common warts trial; next data timing TBA. 03/11/26:- Second Ph3 common warts study with Torii to start in Mid-2026 in US and Japan. 05/12/26:- COVE-2 over 50% enrolled; COVE-3 Ph3 common warts trial still expected to start Mid-2026. 06/22/26:- First U.S. patient dosed in COVE-3 Ph3; Japan also dosed. COVE-2 >50% enrolled; COVE-4 enrolling. 08/06/26:- Ph3 COVE-2/3 are enrolling; topline common warts data expected Mid-2027.
Verification
Confirm timing and program details against the company announcement or filing.